IQVIA’s (IQV) “Outperform” Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of IQVIA (NYSE:IQV) in a research report sent to investors on Wednesday morning,Benzinga reports. Royal Bank of Canada currently has a $270.00 price objective on the medical research company’s stock.

A number of other analysts have also issued reports on IQV. The Goldman Sachs Group lowered their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Evercore ISI dropped their target price on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Truist Financial decreased their price target on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Finally, Redburn Atlantic initiated coverage on shares of IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 target price on the stock. Four research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $256.19.

IQVIA Trading Down 0.7 %

Shares of IQVIA stock opened at $199.06 on Wednesday. IQVIA has a twelve month low of $187.62 and a twelve month high of $261.73. The firm’s 50-day moving average price is $212.86 and its 200 day moving average price is $224.44. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm has a market capitalization of $36.13 billion, a PE ratio of 26.12, a P/E/G ratio of 2.07 and a beta of 1.49.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. FMR LLC lifted its holdings in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in IQVIA during the third quarter worth $147,683,000. 1832 Asset Management L.P. boosted its position in shares of IQVIA by 472.3% during the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after buying an additional 376,595 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of IQVIA in the second quarter valued at $70,610,000. Finally, Impax Asset Management Group plc lifted its stake in IQVIA by 19.3% during the 2nd quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock worth $344,998,000 after acquiring an additional 264,555 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.